Literature DB >> 6375959

[Ac-D-NAL(2)1,4FD-Phe2,D-Trp3,D-Arg6]-LHRH, a potent antagonist of LHRH, produces transient edema and behavioral changes in rats.

F Schmidt, K Sundaram, R B Thau, C W Bardin.   

Abstract

Acute toxicity studies of [Ac-D-NAL(2)1,4FD-Phe2,D-Trp3,D-Arg6]-LHRH (LHRH-A), a potent antagonist of LHRH were performed. Subcutaneous administration of this peptide to rats induced transient edema of the face and extremities. This effect was maximal 3-5 h after peptide administration and subsided by 24 h. These effects were not seen with an LHRH agonist or two other antagonists. This side effects of LHRH-A was peculiar to rats and not observed in mice, rabbits and rhesus monkeys. Intravenous administration led within minutes to depression of spontaneous activity in rats and monkeys. We conclude that some LHRH antagonists produce species specific effects on vascular permeability and spontaneous activity.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6375959     DOI: 10.1016/s0010-7824(84)80008-6

Source DB:  PubMed          Journal:  Contraception        ISSN: 0010-7824            Impact factor:   3.375


  11 in total

1.  Novel analogues of degarelix incorporating hydroxy-, methoxy-, and pegylated-urea moieties at positions 3, 5, 6 and the N-terminus. Part III.

Authors:  Manoj P Samant; Doley J Hong; Glenn Croston; Catherine Rivier; Jean Rivier
Journal:  J Med Chem       Date:  2006-06-15       Impact factor: 7.446

2.  Antagonists of luteinizing hormone releasing hormone bind to rat mast cells and induce histamine release.

Authors:  K Sundaram; A Didolkar; R Thau; M Chaudhuri; F Schmidt
Journal:  Agents Actions       Date:  1988-12

3.  Prolonged inhibition of luteinizing hormone and testosterone levels in male rats with the luteinizing hormone-releasing hormone antagonist SB-75.

Authors:  L Bokser; S Bajusz; K Groot; A V Schally
Journal:  Proc Natl Acad Sci U S A       Date:  1990-09       Impact factor: 11.205

4.  Degarelix, a novel GnRH antagonist, causes minimal histamine release compared with cetrorelix, abarelix and ganirelix in an ex vivo model of human skin samples.

Authors:  Wolfgang Koechling; Rolf Hjortkjaer; László B Tankó
Journal:  Br J Clin Pharmacol       Date:  2010-10       Impact factor: 4.335

5.  The structural features of effective antagonists of the luteinizing hormone releasing hormone.

Authors:  A Janecka; T Janecki; C Bowers; K Folkers
Journal:  Amino Acids       Date:  1994-06       Impact factor: 3.520

6.  Experience with degarelix in the treatment of prostate cancer.

Authors:  Neal D Shore
Journal:  Ther Adv Urol       Date:  2013-02

7.  Treatment of experimental DMBA induced mammary carcinoma with Cetrorelix (SB-75): a potent antagonist of luteinizing hormone-releasing hormone.

Authors:  T Reissmann; P Hilgard; J H Harleman; J Engel; A M Comaru-Schally; A V Schally
Journal:  J Cancer Res Clin Oncol       Date:  1992       Impact factor: 4.553

Review 8.  GnRH agonists and antagonists. Current clinical status.

Authors:  M Filicori; C Flamigni
Journal:  Drugs       Date:  1988-01       Impact factor: 9.546

9.  Highly potent antagonists of luteinizing hormone-releasing hormone free of edematogenic effects.

Authors:  S Bajusz; M Kovacs; M Gazdag; L Bokser; T Karashima; V J Csernus; T Janaky; J Guoth; A V Schally
Journal:  Proc Natl Acad Sci U S A       Date:  1988-03       Impact factor: 11.205

10.  The gonadotropin-releasing hormone (GnRH) agonist-induced initial rise of bioactive LH and testosterone can be blunted in a dose-dependent manner by GnRH antagonist in the non-human primate.

Authors:  O P Sharma; G F Weinbauer; H M Behre; E Nieschlag
Journal:  Urol Res       Date:  1992
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.